Letters to the Editor

FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies

Clinical Hematology, Nantes University Hospital, Nantes, France; CRCI2NA UMR INSERM 1307CNRS 6075 - Nantes Université – Angers University, Nantes
CRCI2NA UMR INSERM 1307CNRS 6075 - Nantes Université – Angers University, Nantes
Clinical Hematology, Limoges University Hospital, Limoges
Clinical Hematology, Limoges University Hospital, Limoges
Clinical Hematology, Bordeaux University Hospital Haut-Lévêque, Pessac
Clinical Hematology, Angers University Hospital, Angers
Clinical Hematology, Besançon University Hospital, Besançon
Clinical Hematology, Grenoble University Hospital, Grenoble
Clinical Hematology, Institut Paoli Calmettes, Marseille
Clinical Hematology, Nice University Hospital, Nice
Clinical Hematology, Poitiers University Hospital, Poitiers
Clinical Hematology, Saint Louis Hospital, Paris
Groupe Francophone des Myélodysplasies, Paris
Groupe Francophone des Myélodysplasies, Paris
Clinical Hematology, Saint Louis Hospital, Paris
Clinical Hematology, Bordeaux University Hospital Haut-Lévêque, Pessac
Clinical Hematology, Nantes University Hospital, Nantes, France; CRCI2NA UMR INSERM 1307CNRS 6075 - Nantes Université – Angers University, Nantes
Groupe Francophone des Myélodysplasies, Paris
Clinical Hematology, Nantes University Hospital, Nantes, France; CRCI2NA UMR INSERM 1307CNRS 6075 - Nantes Université – Angers University, Nantes
Haematologica Early view Nov 21, 2024 https://doi.org/10.3324/haematol.2024.286025